D910MC00001

Research code: D910MC00001
Research name: Randomised, multicentre, double-blind, placebo-controlled phase III research evaluating durvalumab in the treatment of patients with stage II and III non-small-cell lung cancer with minimal residual disease after surgery and therapy with intention to treat (MeRmaiD-2).
Indication: lung cancer
Principal researcher: Ewa Chmielowska, MD, PhD